TY - JOUR
T1 - Primary breast lymphoma
T2 - Patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study
AU - Jeanneret-Sozzi, Wendy
AU - Taghian, Alphonse
AU - Epelbaum, Ron
AU - Poortmans, Philip
AU - Zwahlen, Daniel
AU - Amsler, Beat
AU - Villette, Sylviane
AU - Belkacémi, Yazid
AU - Nguyen, Tan
AU - Scalliet, Pierre
AU - Maingon, Philippe
AU - Gutiérrez, Cristina
AU - Gastelblum, Pauline
AU - Krengli, Marco
AU - Raad, Rita
AU - Ozsahin, Mahmut
AU - Mirimanoff, René Olivier
PY - 2008/4/1
Y1 - 2008/4/1
N2 - Background: To asses the clinical profile, treatment outcome and prognostic factors in primary breast lymphoma (PBL). Methods: Between 1970 and 2000, 84 consecutive patients with PBL were treated in 20 institutions of the Rare Cancer Network. Forty-six patients had Ann Arbor stage IE, 33 stage IIE, 1 stage IIIE, 2 stage IVE and 2 an unknown stage. Twenty-one underwent a mastectomy, 39 conservative surgery and 23 biopsy; 51 received radiotherapy (RT) with (n = 37) or without (n = 14) chemotherapy. Median RT dose was 40 Gy (range 12-55 Gy). Results: Ten (12%) patients progressed locally and 43(55%) had a systemic relapse. Central nervous system (CNS) was the site of relapse in 12 (14%) cases. The 5-yr overall survival, lymphoma-specific survival, disease-free survival and local control rates were 53%, 59%, 41% and 87% respectively. In the univariate analyses, favorable prognostic factors were early stage, conservative surgery, RT administration and combined modality treatment. Multivariate analysis showed that early stage and the use of RT were favorable prognostic factors. Conclusion: The outcome of PBL is fair. Local control is excellent with RT or combined modality treatment but systemic relapses, including that in the CNS, occurs frequently.
AB - Background: To asses the clinical profile, treatment outcome and prognostic factors in primary breast lymphoma (PBL). Methods: Between 1970 and 2000, 84 consecutive patients with PBL were treated in 20 institutions of the Rare Cancer Network. Forty-six patients had Ann Arbor stage IE, 33 stage IIE, 1 stage IIIE, 2 stage IVE and 2 an unknown stage. Twenty-one underwent a mastectomy, 39 conservative surgery and 23 biopsy; 51 received radiotherapy (RT) with (n = 37) or without (n = 14) chemotherapy. Median RT dose was 40 Gy (range 12-55 Gy). Results: Ten (12%) patients progressed locally and 43(55%) had a systemic relapse. Central nervous system (CNS) was the site of relapse in 12 (14%) cases. The 5-yr overall survival, lymphoma-specific survival, disease-free survival and local control rates were 53%, 59%, 41% and 87% respectively. In the univariate analyses, favorable prognostic factors were early stage, conservative surgery, RT administration and combined modality treatment. Multivariate analysis showed that early stage and the use of RT were favorable prognostic factors. Conclusion: The outcome of PBL is fair. Local control is excellent with RT or combined modality treatment but systemic relapses, including that in the CNS, occurs frequently.
UR - https://www.scopus.com/pages/publications/42649091182
U2 - 10.1186/1471-2407-8-86
DO - 10.1186/1471-2407-8-86
M3 - Article
SN - 1471-2407
VL - 8
JO - BMC Cancer
JF - BMC Cancer
M1 - 86
ER -
